Skip to search formSkip to main contentSkip to account menu

LY2784544

Known as: LY 2784544 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

ImidazolesPyrazolesPyridazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
JAK2 inhibition in JAK2V617F-bearing leukemia cells enriches CD34+ leukemic stem cells that are abolished by the telomerase inhibitor GRN163L.
2017
2017
Chemical-biology approach to delineate the mechanism of action of HIV-1 latency reversing agents
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail… 
2013
2013
Ruxolitinib as an emerging treatment in myelofibrosis
Correspondence: Ruben A Mesa Division of Hematology and Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, USA Tel… 
Review
2012
Review
2012
New generation small-molecule inhibitors in myeloproliferative neoplasms
Purpose of reviewMyeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% of the… 
2012
2012
JAK inhibition: the key to treating myeloproliferative neoplasm?
Molecular knowledge of myeloproliferative neoplasms (MPNs) has accelerated in recent years. The discovery of JAK2 mutations in… 
2012
2012
1031 Differential Gene Expression Profile in Response to the Treatment With JAK2 Inhibitors – Ruxolitinib, SAR302503 and LY2784544
2011
2011
Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
Abstract 2814 Background: The majority of primary and secondary MF, PV, and ET neoplasms are characterized by gain-of-function… 
2011
2011
Abstract 2820: LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway
Inflammatory breast cancer (IBC) is more aggressive and deadly than other breast cancers (K Rowan. JNCI. 2009;101(19):1302-1304… 
2010
2010
Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models
Abstract 4087 Introduction: The JAK2-V617F mutation is the most common molecular abnormality in the BCR/ABL-negative myeloid… 
2010
2010
LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients
Abstract 5054 Introduction: The discovery of JAK2 V617F mutation in patients with myeloproliferative disorders (MPD) has opened… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)